The role of iron in anthracycline cardiotoxicity
The clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of severe cardiotoxicity. The mechanisms underlying anthracycline-dependent cardiotoxicity are multiple and remain uncompletely understood, but many observations indicate that interactions with cellular iron metabolis...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00025/full |
| _version_ | 1819098236123611136 |
|---|---|
| author | Elena eGammella Federica eMaccarinelli Paolo eBuratti Stefania eRecalcati Gaetano eCairo |
| author_facet | Elena eGammella Federica eMaccarinelli Paolo eBuratti Stefania eRecalcati Gaetano eCairo |
| author_sort | Elena eGammella |
| collection | DOAJ |
| description | The clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of severe cardiotoxicity. The mechanisms underlying anthracycline-dependent cardiotoxicity are multiple and remain uncompletely understood, but many observations indicate that interactions with cellular iron metabolism are important. Convincing evidence showing that iron plays a role in Doxorubicin cardiotoxicity is provided by the protecting efficacy of iron chelation in patients and experimental models, and studies showing that iron overload exacerbates the cardiotoxic effects of the drug, but the underlying molecular mechanisms remain to be completely characterized. Since anthracyclines generate reactive oxygen species, increased iron-catalyzed formation of free radicals appears an obvious explanation for the aggravating role of iron in Doxorubicin cardiotoxicity, but antioxidants did not offer protection in clinical settings. Moreover, how the interaction between reactive oxygen species and iron damages heart cells exposed to Doxorubicin is still unclear. This review discusses the pathogenic role of the disruption of iron homeostasis in Doxorubicin-mediated cardiotoxicity in the context of current and future pharmacologic approaches to cardioprotection |
| first_indexed | 2024-12-22T00:27:46Z |
| format | Article |
| id | doaj.art-6d8028e50ad2430e91346812bb869bff |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T00:27:46Z |
| publishDate | 2014-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6d8028e50ad2430e91346812bb869bff2022-12-21T18:45:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122014-02-01510.3389/fphar.2014.0002582354The role of iron in anthracycline cardiotoxicityElena eGammella0Federica eMaccarinelli1Paolo eBuratti2Stefania eRecalcati3Gaetano eCairo4University of MilanUniversity of BresciaUniversity of MilanUniversity of MilanUniversity of MilanThe clinical use of the antitumor anthracycline Doxorubicin is limited by the risk of severe cardiotoxicity. The mechanisms underlying anthracycline-dependent cardiotoxicity are multiple and remain uncompletely understood, but many observations indicate that interactions with cellular iron metabolism are important. Convincing evidence showing that iron plays a role in Doxorubicin cardiotoxicity is provided by the protecting efficacy of iron chelation in patients and experimental models, and studies showing that iron overload exacerbates the cardiotoxic effects of the drug, but the underlying molecular mechanisms remain to be completely characterized. Since anthracyclines generate reactive oxygen species, increased iron-catalyzed formation of free radicals appears an obvious explanation for the aggravating role of iron in Doxorubicin cardiotoxicity, but antioxidants did not offer protection in clinical settings. Moreover, how the interaction between reactive oxygen species and iron damages heart cells exposed to Doxorubicin is still unclear. This review discusses the pathogenic role of the disruption of iron homeostasis in Doxorubicin-mediated cardiotoxicity in the context of current and future pharmacologic approaches to cardioprotectionhttp://journal.frontiersin.org/Journal/10.3389/fphar.2014.00025/fullAnthracyclinesDoxorubicinHeartIronReactive Oxygen Species |
| spellingShingle | Elena eGammella Federica eMaccarinelli Paolo eBuratti Stefania eRecalcati Gaetano eCairo The role of iron in anthracycline cardiotoxicity Frontiers in Pharmacology Anthracyclines Doxorubicin Heart Iron Reactive Oxygen Species |
| title | The role of iron in anthracycline cardiotoxicity |
| title_full | The role of iron in anthracycline cardiotoxicity |
| title_fullStr | The role of iron in anthracycline cardiotoxicity |
| title_full_unstemmed | The role of iron in anthracycline cardiotoxicity |
| title_short | The role of iron in anthracycline cardiotoxicity |
| title_sort | role of iron in anthracycline cardiotoxicity |
| topic | Anthracyclines Doxorubicin Heart Iron Reactive Oxygen Species |
| url | http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00025/full |
| work_keys_str_mv | AT elenaegammella theroleofironinanthracyclinecardiotoxicity AT federicaemaccarinelli theroleofironinanthracyclinecardiotoxicity AT paoloeburatti theroleofironinanthracyclinecardiotoxicity AT stefaniaerecalcati theroleofironinanthracyclinecardiotoxicity AT gaetanoecairo theroleofironinanthracyclinecardiotoxicity AT elenaegammella roleofironinanthracyclinecardiotoxicity AT federicaemaccarinelli roleofironinanthracyclinecardiotoxicity AT paoloeburatti roleofironinanthracyclinecardiotoxicity AT stefaniaerecalcati roleofironinanthracyclinecardiotoxicity AT gaetanoecairo roleofironinanthracyclinecardiotoxicity |